“These results are really exciting. This could be a new front in the fight against MS.”
Researchers at Oregon Health & Science University have discovered that an antioxidant designed by scientists more than a dozen years ago to fight damage within human cells significantly helps symptoms in mice that have a multiple sclerosis-like disease.
The antioxidant — called MitoQ — has shown some promise in fighting neurodegenerative diseases. But this is the first time it has been shown to significantly reverse an MS-like disease in an animal.
The discovery could lead to an entirely new way to treat multiple sclerosis, which affects more than 2.3 million people worldwide.
Multiple sclerosis occurs when the body’s immune system attacks the myelin, or the protective sheath, surrounding nerve fibers of the central nervous system. Some underlying nerve fibers are destroyed. Resulting symptoms can include blurred vision and blindness, loss of balance, slurred speech, tremors, numbness and problems with memory and concentration.
The antioxidant research was published in the December edition of Biochimica et Biophysica Acta Molecular Basis of Disease. The research team was led by P. Hemachandra Reddy, Ph.D., an associate scientist in the Division of Neuroscience at OHSU’s Oregon National Primate Research Center.
To conduct their study, the researchers induced mice to contract a disease called experimental autoimmune encephalomyelitis, or EAE, which is very similar to MS in humans. They separated mice into four groups: a group with EAE only; a group that was given the EAE, then treated with the MitoQ; a third group that was given the MitoQ first, then given the EAE; and a fourth “control” group of mice without EAE and without any other treatment.
After 14 days, the EAE mice that had been treated with the MitoQ exhibited reduced inflammatory markers and increased neuronal activity in the spinal cord — an affected brain region in MS — that showed their EAE symptoms were being improved by the treatment. The mice also showed reduced loss of axons, or nerve fibers and reduced neurological disabilities associated with the EAE. The mice that had been pre-treated with the MitoQ showed the least problems. The mice that had been treated with MitoQ after EAE also showed many fewer problems than mice who were just induced to get the EAE and then given no treatment.
“The MitoQ also significantly reduced inflammation of the neurons and reduced demyelination,” Reddy said. “These results are really exciting. This could be a new front in the fight against MS.”
Even if the treatment continues to show promise, testing in humans would be years away. The next steps for Reddy’s team will be to understand the mechanisms of MitoQ neuroprotection in different regions of the brain, and how MitoQ protects mitochondria within the brain cells of the EAE mice. Mitochondria, components within all human cells, convert energy into forms that are usable by the cell.
There is a built-in advantage with MitoQ. Unlike many new drugs, MitoQ has been tested for safety in numerous clinical trails with humans. Since its development in the late 1990s, researchers have tested MitoQ’s ability to decrease oxidative damage in mitochondria.
The Latest on: Multiple sclerosis
via Google News
The Latest on: Multiple sclerosis
- Multiple sclerosis may not put you at risk for breast, colorectal cancerson November 25, 2020 at 1:05 pm
People with multiple sclerosis (MS) may not be at higher risk of developing two of the three cancers that occur most commonly in people with MS, breast and colorectal cancer, than people who don't ...
- MediciNova's MN-166 can reduce retinal thinning in progressive multiple sclerosison November 25, 2020 at 8:58 am
(NASDAQ:MNOV) announces that positive Optical Coherence Tomography (OCT) results from the SPRINT-MS Phase 2b trial of MN-166 (ibudilast) in progressive multiple sclerosis (progressive MS) were ...
- 'Talking about it saves lives': Suicide survivor with multiple sclerosis shares her storyon November 24, 2020 at 2:37 am
Chloe Bellerby survived a suicide attempt as a teen, came from England to play soccer, and is an advocate for mental health and multiple sclerosis.
- Multiple Sclerosis Market Size Report 2020 Global Industry Analysis by Trends, Revenue, Share, Revenue and Forecast to 2025on November 23, 2020 at 2:54 am
Final Report will add the analysis of the impact of COVID-19 on this industry." “Multiple Sclerosis Market” has ...
- Gut-brain axis influences multiple sclerosison November 20, 2020 at 11:10 am
A Basel-led international research team has discovered a connection between the intestinal flora and sites of inflammation in the central nervous system in multiple sclerosis. A specific class of ...
- New research underscores the link between multiple sclerosis and the gut microbiomeon November 20, 2020 at 11:08 am
People with multiple sclerosis have elevated levels of immune cells in their brains that are associated with gut microbiota, the paper finds.
- 1 year after multiple sclerosis diagnosis, WTOP’s Dave Johnson looks back, forwardon November 19, 2020 at 2:06 am
One year after revealing he had been diagnosed with multiple sclerosis, WTOP’s Dave Johnson provides an update on his condition and outlook.
- Leading Neurologist Shares Experiences of Treating Multiple Sclerosis (MS) Patients (FCL Nov. 17)on November 18, 2020 at 5:07 pm
According to an estimate from the National Multiple Sclerosis Society, nearly 1 million people over the age of 18 are living with MS in the United States. MS is a chronic and unpredictable disease of ...
- The Challenges of Relapsing Multiple Sclerosis (MS) Can Add Upon November 18, 2020 at 4:23 am
From experiencing relapses, to worrying about what may come next and managing the demands of life around treatment schedules—the challenges of living with MS can really add up. When they do, it may be ...
- Multiple Sclerosis: Is Therapeutic Angiogenesis a Treatment or Even a Possible Cure?on November 17, 2020 at 9:22 pm
(Zhittya), a private company, announced that it will give a Webinar broadcast on its potential breakthrough therapy to reverse the progression of multiple sclerosis (MS).Currently, no therapies on the ...
via Bing News